American Heart Association/American Stroke Association (AHA/ASA) guidelines for acute ischemic stroke treatment have been expanded, potentially opening the window for more patients to receive therapy or procedures, with the ultimate aim of reducing disability among patients. Guidelines for both clot removal and administration of clot-dissolving therapy were increased to up to 24 hours and to patients with mild stroke, respectively. Medtronic plc, which had been involved in prior research and device advancements, shared executives' comments on the impact.